BioSpace News Archive

Lone Star Bio

Aravive to Participate in the Cantor Fitzgerald Oncology & HemOnc Conference

Aravive, Inc. today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer and Rudy Howard, Chief Financial Officer will participate in the Cantor Fitzgerald Oncology & HemOnc Conference on September 28, 2022 at the Lotte New York Palace Hotel, New York, N.Y.

September 26, 2022
·
1 min read
Drug Development

Qu Biologics to Launch Phase 2B Clinical Trial to Assess Reduction of Postoperative Immune Suppression and Disease Progression in Patients with Late-Stage Colorectal Cancer

Qu Biologics Inc. is pleased to announce it has received Health Canada clearance (No Objection Letter) and institutional-level ethics approval to proceed with a randomized placebo-controlled Phase II multicenter trial to assess the effectiveness of QBECO SSI.

September 26, 2022
·
5 min read
Lone Star Bio

Pain Specialists of America is the First in Texas to Integrate New Spinal Cord Stimulation Device; Provides Tailored Relief to Multiple Pain Areas and Options for Evolving Pain Conditions

Pain Specialists of America announced it is integrating the new Proclaim™ Plus spinal cord stimulation system featuring FlexBurst360™ therapy for patients receiving neuromodulation therapy for chronic pain.

September 26, 2022
·
4 min read
Biotech Beach

Children’s Hospital Los Angeles Identifies Molecular Markers to Increase Precision in Treatment of Retinoblastoma

Retinoblastoma is a cancer of the eye that occurs in infants and toddlers and can lead to loss of vision, loss of one or both eyes, and even death.

September 26, 2022
·
5 min read
Pharm Country

BD, CerTest Biotec Announce US Commercial Launch of Monkeypox Assay

BD, a leading global medical technology company, and CerTest Biotec announced their newly developed molecular polymerase chain reaction assay for monkeypox virus is now commercially available globally, including in the United States, for research use only applications by laboratories.

September 26, 2022
·
3 min read
Policy

Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age

Pfizer Inc. and BioNTech SE announced they have completed a submission to the U.S. Food and Drug Administration requesting Emergency Use Authorization of a 10-µg booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children 5 through 11 years of age.

September 26, 2022
·
22 min read
Policy

Bio-Techne Files Patent Infringement Lawsuit Against Molecular Instruments

Bio-Techne Corporation today announced that it has taken legal action in the United Kingdom to halt the infringement of its patented RNAscope® ISH technology by Molecular Instruments, Inc.

September 26, 2022
·
1 min read
BioMidwest

Centene Subsidiary Selected to Continue Serving Nebraska’s Medicaid Managed Care Members

Centene Corporation announced that its Nebraska subsidiary, Nebraska Total Care, has been awarded the Nebraska Department of Health and Human Services statewide Medicaid managed care contract.

September 26, 2022
·
9 min read
HTG Molecular Diagnostics to Participate in the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference

HTG Molecular Diagnostics, Inc. today announced that management will participate in the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference at the Lotte New York Palace in New York City on Wednesday, September 28, 2022.

September 26, 2022
·
1 min read
Pharm Country

Celularity Publishes New Data in Frontiers in Immunology Demonstrating Placental-derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-infected Cells In Vitro

Celularity Inc. today announced publication of a study in Frontiers in Immunology describing the antiviral role of its placental-derived natural killer (NK) cells (CYNK) in IAV infections.

September 26, 2022
·
6 min read